New depression drug shows promise in early trial

NCT ID NCT06126497

First seen May 01, 2026 · Last updated May 15, 2026 · Updated 5 times

Summary

This study tested a new drug, ropanicant, in 41 adults with moderate to severe major depression. The main goal was to see if the drug is safe and to measure any side effects. Researchers also looked at whether depression symptoms improved using a standard rating scale.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MAJOR DEPRESSIVE DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Cedar Clinical Research, Inc.

    Murray, Utah, 84107, United States

  • CenExel iResearch, LLC

    Decatur, Georgia, 30030, United States

  • CenExel iResearch, LLC

    Savannah, Georgia, 31405, United States

  • Clinical Innovations, Inc

    Bellflower, California, 90706, United States

  • Collaborative Neuroscience Research, LLC

    Torrance, California, 90504, United States

  • Eastside Therapeutic Resource, Inc. dba Core Clinical Research

    Everett, Washington, 98201, United States

  • Innovative Clinical Research, Inc.

    Miami Lakes, Florida, 33016, United States

  • NRC Research Institute

    Orange, California, 92868, United States

  • Neuro behavioral Clinical Research, Inc

    North Canton, Ohio, 44720, United States

  • Precise Research Centers

    Flowood, Mississippi, 39232, United States

Conditions

Explore the condition pages connected to this study.